Matching articles for "Metadol"
Issue 1684 · September 4, 2023 Free
Drugs for Opioid Use Disorder

Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections…

Med Lett Drugs Ther. 2023 Sep 4; 65(1684):137-44 doi:10.58347/tml.2023.1684a
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Issue 1665 · December 12, 2022
Opioids for Pain

A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):193-200
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Issue 1665 · December 12, 2022
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Transdermal Opioid Analgesics

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e199-202
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Issue 1554 · August 27, 2018
Management of Opioid Withdrawal Symptoms

Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment.…

Med Lett Drugs Ther. 2018 Aug 27; 60(1554):137-42
Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment. Withdrawal management without subsequent maintenance treatment is associated with high rates of relapse, overdose death, and HIV and/or hepatitis C virus infection. Several guidelines on management of opioid withdrawal are available. Maintenance treatment of opioid use disorder was reviewed in a previous issue.
Issue 1554 · August 27, 2018
Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms (online only)

View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms

Med Lett Drugs Ther. 2018 Aug 27; 60(1554):e144-6
View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms
Issue 1551 · July 16, 2018
Lofexidine (Lucemyra) for Opioid Withdrawal

The FDA has approved lofexidine ( Lucemyra – US WorldMeds/Salix), a centrally acting alpha 2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):115-7
The FDA has approved lofexidine ( Lucemyra – US WorldMeds/Salix), a centrally acting alpha 2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since 1992, lofexidine is the first nonopioid to be approved in the US for management of opioid withdrawal symptoms. Clonidine ( Catapres , and generics), another central alpha 2 receptor agonist, has been used off-label for this indication for many years.
Issue 1544 · April 9, 2018
Opioids for Pain

Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations…

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):57-64
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Issue 1374 · October 3, 2011
Quetiapine (Seroquel) and QT-Interval Prolongation

The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs…

Med Lett Drugs Ther. 2011 Oct 3; 53(1374):79-80
The FDA has required the manufacturer of the secondgeneration antipsychotic quetiapine (Seroquel) to add a warning to the labeling saying that use of the drug should be avoided in combination with other drugs that prolong the electrocardiographic QTc interval (Table 1). The warning is based only on postmarketing reports of QT-interval prolongation in patients who overdosed on the drug, had concomitant illness, or were taking other drugs known to cause electrolyte imbalances or increase the QT interval. QT prolongation can lead to torsades de pointes, a potentially fatal cardiac arrhythmia.
Issue 1322 · October 5, 2009
Dronedarone (Multaq) for Atrial Fibrillation

Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but…

Med Lett Drugs Ther. 2009 Oct 5; 51(1322):78-80
Dronedarone ( Multaq - Sanofi-Aventis) has been approved by the FDA for oral treatment of atrial fibrillation and flutter. Amiodarone (Cordarone, and others) is the most effective drug for this indication, but has considerable toxicity.